Sarojvisut: An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand

An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand

Sarojvisut et al., Infection & Chemotherapy, doi:10.3947/ic.2022.0127, TCTR20220427005

Sarojvisut et al., An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus.., Infection & Chemotherapy, doi:10.3947/ic.2022.0127, TCTR20220427005

Dec 2022 Source PDF

Twitter
Facebook

All Studies Meta

RCT low risk hospitalized patients in Thailand showing no significant difference with the addition of ivermectin to favipiravir based SOC. Only the abstract is currently available. The trial was registered retrospectively [thaiclinicaltrials.org]. The primary outcome was WHO-category ordinal scale improvement of 2 points at days 3, 7, 14, 21, for which only a single unspecified time point (when almost all patients have recovered) is provided in the abstract (details may be in the full paper). The registration indicates that the intervention was only provided "after laboratory result", without explanation.

1. thaiclinicaltrials.org, https://www.thaiclinicaltrials.org/show/TCTR20220427005.

Important missing comments or errors? Let us know.

risk of ICU admission, 103.8% higher, RR 2.04, p = 0.62, treatment 2 of 157 (1.3%), control 1 of 160 (0.6%).

risk of no improvement, 103.8% higher, RR 2.04, p = 0.62, treatment 2 of 157 (1.3%), control 1 of 160 (0.6%).

recovery time, 3.8% lower, relative time 0.96, p = 0.63, treatment 157, control 160.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Sarojvisut et al., 12 Dec 2022, Randomized Controlled Trial, Thailand, peer-reviewed, 8 authors, study period 1 October, 2021 - 31 May, 2022, dosage 400μg/kg days 1-5, trial TCTR20220427005.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit